Medtech Insight's News We're Watching highlights a few medtech industry developments we are following: Illumina will lay off 111 people from its San Diego headquarters as it comes to grips with the impending Grail divestiture; a team of researchers have devised a way to use spinal cord stimulators to give amputees "feeling" in a leg that is no longer there; Samsung earns FDA de novo for sleep apnea monitor.

Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.

Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.

The company will shift development of INO-4800 to a booster strategy. It also announced it must conduct additional studies of the cervical dysplasia drug VGX-3100 after an FDA meeting.